Skip to search formSkip to main contentSkip to account menu

GS 9350

Known as: 9350, GS, GS-9350, GS9350 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
There are 26 approved antiretroviral drugs available in 2012 in 6 mechanistic classes: reverse transcripatase inhibitors (both… 
Highly Cited
2011
Highly Cited
2011
Objective:To assess the safety and efficacy of two, single-tablet regimens for the initial treatment of HIV infection. Design… 
Review
2011
Review
2011
Elvitegravir is a potent, boosted, once-daily, HIV integrase inhibitor with antiviral activity against wild-type and drug… 
Highly Cited
2010
Highly Cited
2010
GS‐9350 is a new chemical entity under development as a potent, mechanism‐based inhibitor of human cytochrome P450 3A (CYP3A… 
Highly Cited
2010
Highly Cited
2010
Cobicistat (3, GS-9350) is a newly discovered, potent, and selective inhibitor of human cytochrome P450 3A (CYP3A) enzymes. In… 
Highly Cited
2010
Highly Cited
2010
Objective: This study evaluated the relative bioavailability and pharmacokinetics of elvitegravir (EVG), emtricitabine (FTC… 
2009
2009
2009
2009
  • AIDS patient care and STDs
  • 2009
  • Corpus ID: 36341942